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We read with interest the paper by Peiseler et al., and the accom-
panying editorial by Oo and Adams, reporting that in patients
with autoimmune hepatitis (AIH), regulatory T cells (T-regs) are
‘fully functional and not reduced in frequency’ [1]. These data con-
trast with our ﬁndings of T-reg impairment in AIH, especially dur-
ing active disease [2–5]. This discrepancy is attributed by the
authors of the paper and the editorial to their use of an ‘improved’
methodology to deﬁne ‘true’ T-regs, i.e. CD4+CD25highCD127low
cells.
We wish to raise a few discussion points.
A key ﬁnding of Peiseler et al. is that ‘the frequency of
CD4+CD25highCD127lowFOXP3pos cells in blood of AIH patients was
not reduced compared to healthy subjects’. These results are similar
to our recent data [6] – of which, however, they do not appear to
be aware – showing that CD4+CD25highCD127neg cell numbers are
similar in patients with AIH, their ﬁrst degree relatives and
healthy subjects. In contrast to them, we show that these cells,
similarly to CD4+CD25high T-regs [2–5], do have a decreased
function in patients compared to healthy relatives and controls.
The discrepancy between our ﬁndings and those of Peiseler et
al., therefore, relates mainly to T-reg function. Methodological
approaches are a plausible explanation for this divergence. Both
groups use suppression of CD4+CD25neg cell proliferation as read-
out of the suppressor function, but we use the more physiological
suppressor/effector ratio of 1:8, while, somewhat surprisingly,
Peiseler et al. use a ratio of 1:1, which is utterly non-physiologi-
cal. In fact, from the limited information provided in the method-932 Journal of Hepatologyology, it is unclear whether their results are due to a dilution of
the CD4+CD25neg cells more than to suppression.
A few other points: to purify CD4+CD25high cells, Peiseler et al.
use a modiﬁed technique claimed to yield CD4 cells with high
CD25 density. The authors, however, in contrast to us [4], do
not provide evidence that their cells are indeed CD25 high. More-
over, they state that the purity of their CD4+CD25high cells ‘was
always about 80–90%’, a value lower that what we have consis-
tently reported (>95%).
The authors suggest that the majority of their CD4+CD25+ cells
may represent activated T lymphocytes, whose number mirrors
disease activity. This would conﬁrm old – not cited – data from
our group [7,8]. We have, however, shown that puriﬁed
CD4+CD25+ cells expressing high levels of CD25 have suppressor
function [2–5]. The difference between our results and those of
Peiseler et al. is likely to be due to the different protocol used
for the isolation of CD4+CD25high cells. Moreover, Peiseler et al.
use a gating technique that yields numbers of T-regs (their
Fig. 1B) vastly lower than those reported in the literature [10]
and by us when we used markers similar to theirs [6]. No sufﬁ-
cient technical details, however, are provided to retrace their
protocol.
The explanation suggested by the authors, that our results are
different because we study paediatric AIH patients, might be of
relevance, as indeed our patients have paediatric onset AIH and
have much more frequently type 2 AIH than their adult cohort.
However, results very similar to those obtained in paediatric
patients have been reported in adult patients with AIH [9].2012 vol. 57 j 921–934
In conclusion, we would urge the authors to be more cautious
in the interpretation of their and published observations and we
agree with the editorial comment that improved methodologies
will help better understand the role of T-regs in disease.
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Reply to: ‘‘Regulatory T cells in autoimmune hepatitis’’
To the Editor:
We read with interest the comment by Longhi et al. on our paper
on Tregs in autoimmune hepatitis (AIH) [1] and the accompany-
ing editorial by Oo and Adams [2]. The discrepant results by
Longhi et al. and us on Treg function in autoimmune hepatitis
(AIH) may originate from the use of different methods to purify
and assess the suppressor activity of Tregs [3,4]. Therefore, we
will reply to the criticism by comparing the methodologies used
by the Kings College group and by us, and explain why we chose
the methodology as we did.
To determine Treg function, Longhi et al. used the 3H-thymi-
dine assay. First, Treg were puriﬁed with magnetic beads to
enrich CD25+ CD4+ T cells; indeed, >95% of these cells were
CD25+. These CD25+ cells were then co-cultured together with
CD25 CD4+ T cells at a ratio of 1:8 for several days, after which
3H-thymidine was added to determine proliferation of the cell
mixture. We also enriched CD25+ CD4+ T cells with magnetic
beads, and found that >95% of these cells expressed CD25. How-
ever, in humans, CD25 alone cannot be used as a marker for Treg
cells, since, in human blood, up to 30% of the CD4+ T cells can
express CD25, but only 1–2% of these are functional suppressors
[4]. In contrast to Longhi et al., we therefore further characterised
the CD25+ cells by staining Foxp3 and CD127 (Fig. 2A of our man-
uscript), demonstrating that the majority of these cells (80–90%)
were indeed Treg. More importantly, we also characterised the
CD25 effector population by showing that more than 90% of
cells were non-Tregs (Fig. 2A). We then determined Treg function
with the CFSE dilution assay, in which only CD25 CD4+ effector
T cells were labelled with CFSE and subsequently co-cultured
together with the unlabelled CD25+ Treg fraction. The great
advantage of the CFSE assay over the 3H-thymidine assay is that
it is able to speciﬁcally evaluate the proliferation of the CD25
CD4+ responder T cell population [5–7]. The 3H-thymidine assay,
in contrast, cannot distinguish which cells in the co-culture have
incorporated 3H-thymidine, which can result in false estimates of
Treg suppression [7]. In addition, unlike the CFSE assay, 3H-thy-
midine assays can only give a snapshot of proliferation for the
period of time during which 3H-thymidine was present in the
culture [7]. Moreover, unlike murine Treg cells, human Treg cells
have a tendency to proliferate after activation [4], making the dis-
tinction of those cells that actually proliferated in the culture
even more problematic. We thus would like to refer to Sakaguchi
et al. [4] who state that ‘this indicates that thymidine uptake by cul-
tured Treg and effector cells is not appropriate to assess suppressive
activity of human Treg cells’, and instead ‘propose that it is more
accurate to assess dilution of CFSE in effector T cells to determine
the percentage and number of proliferating cells’.
Another point addressed by Longhi et al. is that we cultured
Treg cells and effector cells at a ratio of 1:1, instead of 1:8 as
they did, arguing that this ratio is ‘utterly non-physiological’.
We do agree that this assay is non-physiological, as basically
any in vitro assay. However, the aim of the assay was not to
determine the Treg physiology, but to assess their suppressive
potential, which, as others have shown [5–7], can be reasonably
performed with the CFSE assay using ratios in a range between
2:1 and 1:4.
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